Bring your biosimilar to market faster by tapping into unparalleled data, technology, advanced analytics, and scientific expertise.
Biological medicines have transformed the treatment of serious and chronic diseases. Yet ensuring sustainable patient access to these therapies remains a challenge for healthcare systems worldwide.
Biosimilars can broaden treatment options and support access to biological medicines. However, developing a biosimilar is fundamentally different from developing a conventional generic.
A biosimilar is a biological medicine highly similar to an already approved reference medicine, with no clinically meaningful differences in quality, safety and efficacy. Because biological medicines are complex and inherently variable, biosimilars are not considered exact generic copies.1,2
For developers, the strategic challenge is therefore not simply to satisfy individual regulatory requirements. It is to design a scientifically rigorous global development program that can work across multiple markets, make effective use of existing evidence and account for meaningful local differences without unnecessary duplication.
Global principles, local realities
Regulatory approaches to biosimilars have evolved considerably over the past two decades.
The World Health Organization (WHO) 2022 guidelines provide globally acceptable principles for biosimilar licensing. Once similarity has been demonstrated, licensing can rely in part on nonclinical and clinical data generated for the originator product. The guidelines can also be adopted by national regulatory authorities or used as a basis for national regulatory frameworks.1
The European Union has substantial experience in this area, having approved its first biosimilar in 2006. The European Medicines Agency (EMA) describes biosimilar development as a product-specific, stepwise comparability exercise in which quality and analytical evidence help determine the type and extent of additional nonclinical and clinical evidence required.2,3
Regulatory frameworks are also continuing to develop in other markets. In Saudi Arabia, the Saudi Food and Drug Authority (SFDA) issued its General Guideline on Regulatory and Scientific Requirements for Biosimilar Approval in June 2026.4
Across Africa, regulatory cooperation is also advancing. In May 2026, WHO and the African Medicines Agency (AMA) signed a Framework Agreement for Collaboration to strengthen regulatory systems and promote harmonization, convergence and reliance across the continent. Although the agreement is not specific to biosimilars, it may help create a more coordinated regulatory environment for health products across Africa.5
Together, these developments point towards greater regulatory alignment, but not regulatory uniformity. Developers must still determine which elements of a global evidence package can be used across markets, where additional requirements may apply and how those differences should influence development and submission strategies.
Regulatory strategy begins before submission
Many decisions that shape a biosimilar program are made long before a dossier reaches a health authority.
Reference-product selection, analytical comparability, manufacturing strategy, clinical development, immunogenicity, indication extrapolation, pharmacovigilance and labeling are interconnected considerations that can influence the viability of a global development program.1
Regulatory intelligence therefore needs to go beyond monitoring new guidance. It should translate evolving requirements and scientific expectations into development decisions early enough to influence study design, evidence generation and market sequencing.
For a multi-market program, four questions are particularly important:
- Where are regulatory requirements converging?
- Which evidence can be leveraged across markets?
- Where could additional evidence or local engagement be required?
- How should priority markets and submissions be sequenced?
Considering these questions early enables regulatory strategy to become an integral part of global development planning rather than a series of country-by-country activities undertaken at the point of submission.
At the same time, the science underpinning biosimilar development continues to evolve. WHO's revised framework provides greater flexibility and seeks to reduce unnecessary regulatory burden while maintaining standards for quality, safety and efficacy. WHO also identifies implementation of its biosimilar guidelines as an increasingly important mechanism for regulatory convergence.6
This does not lower the scientific standard for demonstrating bio-similarity. Instead, it places greater emphasis on determining what evidence is needed to address remaining scientific uncertainty and avoiding studies that add limited value.
For companies pursuing multiple markets, regulatory strategies therefore need to reflect not only today's requirements, but also changes in regulatory science as they occur.
Approval is only one part of access
Marketing authorization is critical, but approval alone does not ensure that a biosimilar reaches patients or achieves sustainable use.
WHO has identified barriers beyond the regulatory pathway, including reimbursement and financing, treatment guidelines, approaches to interchangeability and substitution, market factors, and acceptance among healthcare professionals and patients.7
A successful biosimilar strategy must therefore connect regulatory planning with evidence generation and market access. Considering these factors during development can help sponsors anticipate the evidence and implementation needs that may emerge after approval.
The path to patient access starts well before marketing authorization.
Connecting global insight with local execution
For biosimilar developers, multi-market development requires a global perspective supported by local scientific, regulatory and access insight.
Since 2009, IQVIA has worked on biosimilars involving more than 30 unique reference biologics and delivered more than 80 biosimilar studies across therapeutic areas.8 The IQVIA Biosimilars Center of Excellence brings together market intelligence, strategy and protocol development, trial operations, regulatory support, and medical and clinical expertise.
Beyond development, IQVIA's Global Regulatory Affairs Lifecycle Management (LCM) team provides worldwide support throughout the product lifecycle, including marketing authorization applications, regulatory strategy, scientific advice and regulatory consultations, lifecycle management activities, post-approval variations, renewals, and regulatory maintenance. By combining global regulatory expertise with local market knowledge, the team supports sponsors in achieving, maintaining, and expanding product registrations across diverse regulatory environments, helping to sustain market access throughout the product lifecycle.
Integrating these capabilities can help sponsors evaluate how evidence may translate across priority markets, identify potential gaps earlier and align development decisions with regulatory and access considerations.
Growing harmonization, cooperation and regulatory reliance may create opportunities to use existing evidence more efficiently. However, individual market requirements and implementation pathways will continue to matter.
The strategic advantage lies in maintaining a consistent global development rationale while adapting execution to the scientific, regulatory and access realities of individual markets.
Looking ahead
The biosimilar regulatory environment will continue to evolve as scientific understanding grows and authorities gain further experience.
The European Union now has two decades of experience following its first biosimilar approval in 2006, while WHO continues to promote regulatory convergence and individual markets are developing and refining their own frameworks.1,2,4,6
For biosimilar developers, the priority is clear: identify where regulatory requirements converge, understand where meaningful local differences remain and incorporate those insights into development and access planning from the outset.
Ultimately, regulatory approval is a means to an end.
The broader value of biosimilars is realized when strong science, informed regulatory strategy and effective local execution help quality-assured biological medicines reach more patients.
References
- World Health Organization. Guidelines on evaluation of biosimilars. WHO Technical Report Series No. 1043, Annex 3. Geneva: World Health Organization; 2022. who.int
- European Medicines Agency. Biosimilar medicines: overview. ema.europa.eu
- European Medicines Agency. Biosimilar medicines: marketing authorisation. ema.europa.eu
- Saudi Food and Drug Authority. General Guideline on Regulatory and Scientific Requirements for Biosimilar Approval. Riyadh: Saudi Food and Drug Authority; 2026. sfda.gov.sa
- World Health Organization. WHO and African Medicines Agency launch landmark framework to strengthen access to quality-assured health products in Africa. Published May 21, 2026. who.int
- World Health Organization. Biosimilars. Biological standardization. who.int
- World Health Organization. Updates on biosimilars. Member State Meeting. December 1, 2022. apps.who.int
- IQVIA. Biosimilars. https://www.iqvia.com/solutions/therapeutics/biosimilars
Related solutions
